Physician profile
Claire Sims
NPI 1215513932
$500.85
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $112 · 2023: $111 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $122.28 | 2021 | |
| Pfizer INC. | $80.00 | 2022 | |
| Kerecis Limited | $63.23 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $60.36 | 2022-2024 | Collagenase Santyl, Grafix Pl |
| Lilly USA, LLC | $48.26 | 2021-2022 | |
| Convatec INC. | $28.54 | 2023 | |
| Molnlycke Health Care US, LLC | $24.73 | 2023 | Mepilex, Mepilex Lite, Mepilex Border Flex |
| Cardiovascular Systems INC. | $22.83 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.45 | 2021 | |
| Kci USA, INC. | $21.31 | 2023 | 3m Cavilon, V.A.C. Dermatac, Activ.A.C. |
| Cashflow Solutions, LLC | $6.86 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.